Clovis Oncology Inc CLVS is trading higher Thursday morning after the company announced data from the monotherapy arm of the ATHENA trial achieved the primary endpoint of significantly improved investigator-assessed progression-free survival compared with the placebo.
Based on the results, Clovis plans to submit a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration during the second quarter.
The sNDA submission will be followed by a Type II Variation in the third quarter for a first-line maintenance treatment indication for women with advanced ovarian cancer who have responded to first-line platinum-based chemotherapy regardless of biomarker status.
Clovis is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents.
See Also: 23 Stocks Moving in Thursday's Pre-Market Session
CLVS 52-Week Range: $1.35 - $7.35
The stock was up 47.3% at $2.43 at time of publication.
Photo: fernandozhiminaicela from Pixabay.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
